___MOLOGEN AG__Dabeisein ist Alles__Jetzt gehts richtig los_ (Seite 4940)
eröffnet am 01.12.05 19:44:38 von
neuester Beitrag 24.04.24 20:35:51 von
neuester Beitrag 24.04.24 20:35:51 von
Beiträge: 73.216
ID: 1.023.882
ID: 1.023.882
Aufrufe heute: 6
Gesamt: 6.132.558
Gesamt: 6.132.558
Aktive User: 0
ISIN: DE000A2LQ900 · WKN: A2LQ90
0,0600
EUR
-0,33 %
-0,0002 EUR
Letzter Kurs 27.11.20 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6220 | +108,03 | |
| 55,50 | +36,03 | |
| 1,7870 | +28,56 | |
| 1,0300 | +27,16 | |
| 1,0500 | +23,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -31,17 | |
| 2,6200 | -43,04 | |
| 0,7900 | -45,89 | |
| 1,0200 | -53,64 | |
| 4,1200 | -66,17 |
Beitrag zu dieser Diskussion schreiben
Feedback
danke für den link! 
finde die ausführungen zu dendreon/mologen auch sehr interessant!!
loooooong & coooooool
finde die ausführungen zu dendreon/mologen auch sehr interessant!!
loooooong & coooooool
Die Diskussion mit Prof. Dr. Burghardt Wittig und Prof. Hans-Georg Rammensee, Immuntherapien und Oligonukleoide in der Krebstherapie, ist sehr interessant. Was allgemein bekannt ist, dass Prof. Hans-Georg Rammensee Mitbegründer der Immatics ist und bei mehreren Patenten auch Mologen-Technologie einsetzte. Mologen verfolgt aber offensichtlich eine, eventuell schon sehr konkrete, andere Unternehmensstrategie.
http://german-science-day.de/content/webcast-0#clip=1b898836…
http://german-science-day.de/content/webcast-0#clip=1b898836…
Antwort auf Beitrag Nr.: 42.711.113 von LloydBrigman am 07.02.12 11:29:46Ja, und zwischen den beiden Parties wird dann gewöhnlich wieder hart gearbeitet. Man muss sich die nächste Party ja leisten können. 
Antwort auf Beitrag Nr.: 42.710.984 von pokemon am 07.02.12 11:12:06Arbeitest du eigentlich bei der Bahn? Die erstellen dort nämlich auch Fahrpläne, die sie dann nicht einhalten.
...für etwas was nur hin und her ruckelt benötigt man doch keine Notbremse.
Die Party/Show ist erst einmal vorbei. Dann wird gewöhnlich auch die Schminke wieder abgenommen.
Bis zu nächsten Party/Show...
Die Party/Show ist erst einmal vorbei. Dann wird gewöhnlich auch die Schminke wieder abgenommen.
Bis zu nächsten Party/Show...
Trading Spotlight
auch das ziehen der notbremse hält der fahrstuhl nicht wirklich vom fahrplan nach 8++ im februar 2012 ab! 
und da gibt es noch Cancer Vaccines made in germany
... if GSK can get through the phase 3 trial it could be a huge boost to its revenues, since Dendreon set a very high price standard that received Medicare reimbursement approval. The companies developing these new treatments that have shown more effective than the current standard of care will all be in for windfalls.
InvestorPlace
Stocks to Watch on Cancer Vaccines’ Huge Financial Potential
Tests for several new therapeutic vaccines are well underway Nov 21, 2011, 7:15 am EST | By Barry Cohen, Health Care Writer
In a 2009 article in Time magazine, developing a vaccine against cancer was likened to creating the biological version of a stealth weapon encased in a smart bomb equipped with a guided missile. A challenge, to say the least. Yet, despite years of disappointment with efforts to get the body’s own immune system to attack tumors and fight diseases, it appears that we are on the cusp of a new era in vaccines.
Vaccines, of course, are not novel. For years they’ve been used to provide lasting protection against infection. Therapeutic vaccines are different. They’re intended to actually combat disease once it appears in the body. In April 2010, the FDA approved the first therapeutic vaccine, Dendreon’s (NASDAQNDN) Provenge, which was shown to extend life about four months in men with a certain type of metastatic prostate cancer. The vaccine provokes an immune response against a particular antigen, or identifying molecule, found on most prostate cancer cells.
Cancer vaccines seem ideally suited for use in patients whose disease has already been diagnosed and treated with surgery, chemotherapy or radiation. They would then be immunized as a way to prevent the cancer from coming back and spreading. Such metastases are actually the leading cause of death from cancer.
Given the huge financial potential of therapeutic cancer vaccines, investors may want to closely follow the progress being made by the following companies currently testing such vaccines in humans:
ImmunoCellular Therapeutics (OTC BB:IMUC.OB ) is testing ICT-107 in patients with glioblastoma, a fast-moving and deadly form of brain cancer. The company recently began a Phase II trial of the vaccine candidate after an initial study in 16 newly diagnosed glioblastoma patients delivered a three-year overall survival rate of 55%, compared with 16% based on traditional methods of care.
???
Inovio Pharmaceuticals (NYSE:INO) has VGX-3100, a therapeutic DNA vaccine candidate now in Phase II testing for the treatment of cervical dysplasia and cancer caused by two types of human papillomavirus (HPV). These sexually transmitted strains are thought to cause up to 70% of cervical cancer cases.
GlaxoSmithKline (NYSE:GSK) is betting it has found a mixture of proteins that can boost the body’s natural ability to battle several kinds of cancers, all of which express the MAGE-A3 antigen. The company is in the midst of Phase III trials, testing its vaccine candidate against metastatic melanoma and non-small-cell lung cancer.
Advaxis (OTC BB:ADXS.OB ) is working to develop an immunotherapy against HPV, the most prevalent sexually transmitted disease in the U.S. Its therapeutic vaccine candidate, ADXS-HPV, is being evaluated in four Phase II clinical trials, including two trials in cervical cancer and one in head and neck malignancies.
Also, privately held GlobeImmune has a deal worth $40 million upfront and up to $500 million with Celgene (NASDAQ:CELG) for the development of cancer vaccines. GlobeImmune is developing Tarmogens — Targeted Molecular Immunogens — for cancer and infectious disease. Its lead oncology candidate is GI-4000, a vaccine that targets pancreatic cancer caused by mutated versions of specific protein.
InvestorPlace
Stocks to Watch on Cancer Vaccines’ Huge Financial Potential
Tests for several new therapeutic vaccines are well underway Nov 21, 2011, 7:15 am EST | By Barry Cohen, Health Care Writer
In a 2009 article in Time magazine, developing a vaccine against cancer was likened to creating the biological version of a stealth weapon encased in a smart bomb equipped with a guided missile. A challenge, to say the least. Yet, despite years of disappointment with efforts to get the body’s own immune system to attack tumors and fight diseases, it appears that we are on the cusp of a new era in vaccines.
Vaccines, of course, are not novel. For years they’ve been used to provide lasting protection against infection. Therapeutic vaccines are different. They’re intended to actually combat disease once it appears in the body. In April 2010, the FDA approved the first therapeutic vaccine, Dendreon’s (NASDAQ
NDN) Provenge, which was shown to extend life about four months in men with a certain type of metastatic prostate cancer. The vaccine provokes an immune response against a particular antigen, or identifying molecule, found on most prostate cancer cells.Cancer vaccines seem ideally suited for use in patients whose disease has already been diagnosed and treated with surgery, chemotherapy or radiation. They would then be immunized as a way to prevent the cancer from coming back and spreading. Such metastases are actually the leading cause of death from cancer.
Given the huge financial potential of therapeutic cancer vaccines, investors may want to closely follow the progress being made by the following companies currently testing such vaccines in humans:
ImmunoCellular Therapeutics (OTC BB:IMUC.OB ) is testing ICT-107 in patients with glioblastoma, a fast-moving and deadly form of brain cancer. The company recently began a Phase II trial of the vaccine candidate after an initial study in 16 newly diagnosed glioblastoma patients delivered a three-year overall survival rate of 55%, compared with 16% based on traditional methods of care.
???
Inovio Pharmaceuticals (NYSE:INO) has VGX-3100, a therapeutic DNA vaccine candidate now in Phase II testing for the treatment of cervical dysplasia and cancer caused by two types of human papillomavirus (HPV). These sexually transmitted strains are thought to cause up to 70% of cervical cancer cases.
GlaxoSmithKline (NYSE:GSK) is betting it has found a mixture of proteins that can boost the body’s natural ability to battle several kinds of cancers, all of which express the MAGE-A3 antigen. The company is in the midst of Phase III trials, testing its vaccine candidate against metastatic melanoma and non-small-cell lung cancer.
Advaxis (OTC BB:ADXS.OB ) is working to develop an immunotherapy against HPV, the most prevalent sexually transmitted disease in the U.S. Its therapeutic vaccine candidate, ADXS-HPV, is being evaluated in four Phase II clinical trials, including two trials in cervical cancer and one in head and neck malignancies.
Also, privately held GlobeImmune has a deal worth $40 million upfront and up to $500 million with Celgene (NASDAQ:CELG) for the development of cancer vaccines. GlobeImmune is developing Tarmogens — Targeted Molecular Immunogens — for cancer and infectious disease. Its lead oncology candidate is GI-4000, a vaccine that targets pancreatic cancer caused by mutated versions of specific protein.
Antwort auf Beitrag Nr.: 42.707.313 von paulixchen am 06.02.12 17:59:02hallo pauli,hast du in mologen gewechselt?
starkes volumen heute,über 23000 stck.!
aber leider..
servus
starkes volumen heute,über 23000 stck.!
aber leider..
servus
Durchsuchen
